emerg
late
initi
outbreak
china
involv
case
sever
critic
cours
sever
present
correspond
usag
viru
receptor
express
predominantli
lung
caus
earli
onset
sever
symptom
receptor
tropism
thought
determin
pathogen
also
aid
control
sever
acut
respiratori
syndrom
sar
howev
report
case
mild
upper
respiratori
tract
symptom
suggest
potenti
preor
oligosymptomat
transmiss
urgent
need
inform
bodi
site
specif
viru
replic
immun
infect
provid
detail
virolog
analysi
nine
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
pharyng
viru
shed
high
first
week
symptom
peak
x
rna
copi
per
throat
swab
day
infecti
viru
readili
isol
throatand
lungderiv
sampl
stool
sampl
spite
high
viru
rna
concentr
blood
urin
never
yield
viru
activ
replic
throat
confirm
viral
replic
rna
intermedi
throat
sampl
sequencedistinct
viru
popul
consist
detect
throatand
lung
sampl
one
patient
shed
viral
rna
sputum
outlast
end
symptom
seroconvers
occur
day
follow
rapid
declin
viral
load
present
mild
upper
respiratori
tract
ill
close
genet
related
sever
acut
respiratori
syndrom
coronaviru
sarscov
caus
agent
predomin
express
lower
respiratori
tract
believ
determin
natur
histori
sar
lower
respiratori
tract
infect
wherea
posit
detect
clinic
specimen
upper
respiratori
tract
describ
observ
address
princip
differ
sar
term
clinic
patholog
herestudi
patient
enrol
acquir
infect
upon
known
close
contact
index
case
therebi
avoid
represent
bias
due
symptombas
case
definit
patient
treat
singl
hospit
munich
germani
virolog
test
done
two
closelycollabor
laboratori
use
standard
technolog
rtpcr
viru
isol
confirm
result
base
almost
individu
sampl
due
extrem
high
congruenc
result
data
present
togeth
serolog
data
base
result
one
laboratori
patient
part
larger
cluster
epidemiologicallylink
case
occur
januari
rd
munich
germani
discov
januari
th
et
al
accompani
manuscript
present
studi
use
sampl
taken
clinic
cours
hospit
well
initi
diagnost
test
admiss
case
initi
diagnost
test
done
laboratori
origin
sampl
retriev
retest
rigor
qualiti
standard
present
studi
first
understand
whether
describ
clinic
present
sole
caus
infect
sampl
patient
test
panel
typic
agent
respiratori
viral
infect
includ
influenza
viru
b
rhinoviru
enteroviru
respiratori
syncyti
viru
human
parainfluenza
viru
human
metapneumoviru
adenoviru
human
bocaviru
interestingli
coinfect
detect
patient
patient
initi
diagnos
rtpcr
oroor
nasopharyng
swab
specimen
specimen
type
collect
whole
clinic
cours
patient
discern
differ
viral
load
detect
rate
compar
nasov
oropharyng
swab
figur
earliest
swab
taken
day
symptom
symptom
often
mild
prodrom
swab
patient
taken
day
test
posit
averag
viru
rna
load
copi
per
whole
swab
day
maximum
copiesswab
swab
sampl
taken
day
averag
viral
load
copi
per
swab
detect
rate
last
swab
sampl
taken
day
postonset
averag
viral
load
sputum
x
copi
per
ml
maximum
copi
per
ml
swab
sampl
limit
sensit
initi
diagnosi
case
sar
analyz
first
pair
swab
sputum
sampl
taken
occas
seven
patient
tabl
sampl
taken
day
postonset
two
case
swab
sampl
clearli
higher
viru
concentr
sputum
sampl
indic
differ
greater
threshold
cycl
ct
valu
opposit
true
two
other
case
case
similar
concentr
sampl
type
none
urin
sampl
none
serum
sampl
test
posit
rna
understand
infect
live
viru
isol
attempt
multipl
occas
clinic
sampl
figur
wherea
viru
readili
isol
first
week
symptom
signific
fraction
sampl
swab
sputum
sampl
isol
obtain
sampl
taken
day
spite
ongo
high
viral
load
viru
isol
stool
sampl
never
success
irrespect
viral
rna
concentr
base
total
sampl
taken
day
six
twelv
four
patient
viru
isol
success
also
depend
viral
load
sampl
contain
copiesml
copi
per
sampl
never
yield
isol
swab
sputum
interpol
base
probit
model
done
obtain
laboratorybas
infect
criteria
discharg
patient
figur
e
f
high
viral
load
success
isol
earli
throat
swab
suggest
potenti
viru
replic
upper
respiratori
tract
tissu
obtain
proof
activ
viru
replic
absenc
histopatholog
conduct
rtpcr
test
identifi
viral
subgenom
messeng
rna
sgrna
directli
clinic
sampl
viral
sgrna
transcrib
infect
cell
packag
virion
therefor
indic
presenc
activelyinfect
cell
sampl
viral
sgrna
compar
viral
genom
rna
sampl
sputum
sampl
taken
day
time
activ
replic
sputum
obviou
patient
per
longitudin
viral
load
cours
see
mean
normal
sgrna
per
genom
ratio
figur
swab
taken
day
rang
sgrna
detect
swab
thereaft
togeth
data
indic
activ
replic
throat
first
day
symptom
onset
minim
indic
replic
stool
obtain
method
figur
studi
sequenc
full
viru
genom
patient
exchang
first
detect
one
patient
later
transmit
patient
cluster
accompani
manuscript
first
patient
mutat
found
throat
swab
sputum
sampl
day
still
show
origin
allel
snp
analyz
rtpcr
sanger
sequenc
sequenti
sampl
avail
patient
tabl
presenc
separ
genotyp
throat
swab
sputum
strongli
support
suspicion
independ
viru
replic
throat
rather
passiv
shed
lung
daili
measur
viral
load
sputum
pharyng
swab
stool
summar
figur
gener
viral
rna
concentr
high
initi
sampl
patient
except
one
throat
swab
rna
concentr
seem
alreadi
declin
time
first
present
sputum
rna
concentr
declin
slowli
peak
first
week
symptom
three
eight
patient
stool
rna
concentr
also
high
cours
viral
rna
concentr
stool
seem
reflect
cours
sputum
mani
case
eg
figur
b
c
one
case
independ
replic
intestin
tract
seem
obviou
cours
stool
rna
excret
figur
wherea
symptom
mostli
wane
end
first
week
tabl
viral
rna
remain
detect
throat
swab
well
second
week
stool
sputum
sampl
remain
rnaposit
even
longer
period
spite
full
resolut
symptom
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
case
compar
mild
cours
tabl
two
patient
show
sign
pneumonia
case
sputum
viral
load
show
late
high
peak
around
day
wherea
sputum
viral
load
declin
time
patient
figur
f
g
seroconvers
detect
igg
igm
immunofluoresc
use
cell
express
spike
protein
viru
neutral
assay
use
tabl
earli
sera
taken
day
none
patient
show
detect
antibodi
patient
monitor
long
enough
yield
serum
sampl
two
week
show
neutral
antibodi
titer
level
suggest
correl
clinic
cours
note
case
lowest
viru
neutral
titer
end
week
seem
shed
viru
stool
prolong
time
figur
result
differenti
recombin
immunofluoresc
assay
indic
signific
rise
titer
four
endem
human
coronavirus
tabl
clinic
cours
subject
studi
mild
youngto
middleag
profession
without
signific
underli
diseas
apart
one
patient
case
first
test
symptom
still
mild
prodrom
stage
period
patient
would
present
gener
awar
circul
pandem
diseas
diagnost
test
suggest
simpl
throat
swab
provid
suffici
sensit
stage
infect
stark
contrast
sar
instanc
nasal
nasopharyng
swab
sampl
test
posit
rtpcr
sar
patient
hong
kong
also
viral
load
differ
consider
sar
took
day
onset
peak
rna
concentr
copi
per
swab
reach
present
studi
peak
concentr
reach
day
time
higher
success
live
viru
isol
throat
swab
anoth
strike
differ
sar
isol
rare
success
altogeth
suggest
activ
viru
replic
upper
respiratori
tract
tissu
minim
express
found
sarscov
therefor
thought
replic
time
concurr
use
receptor
sarscov
correspond
highli
similar
excret
kinet
sputum
activ
replic
lung
sarscov
found
sputum
mean
concentr
copi
per
ml
correspond
observ
made
wherea
proof
replic
histopatholog
await
extend
tissu
tropism
replic
throat
strongli
support
studi
sgrnatranscrib
cell
throat
swab
sampl
particularli
first
day
symptom
strike
addit
evid
independ
replic
throat
provid
sequenc
find
one
patient
consist
show
distinct
viru
throat
oppos
lung
critic
major
patient
present
studi
seem
alreadi
beyond
one
interest
hypothes
explain
potenti
extens
tropism
throat
presenc
polybas
furintyp
cleavag
site
junction
spike
protein
present
sarscov
insert
polybas
cleavag
site
region
sarscov
shown
lead
moder
discern
gain
fusion
activ
might
result
increas
viral
entri
tissu
low
densiti
express
combin
high
viru
rna
concentr
occasion
detect
sgrnacontain
cell
stool
indic
activ
replic
gastrointestin
tract
activ
replic
also
suggest
much
higher
detect
rate
compar
merscoronaviru
found
stoolassoci
rna
sampl
patient
hospit
riyadh
saudi
arabia
viru
passiv
present
stool
swallow
respiratori
secret
similar
detect
rate
merscov
would
expect
replic
gastrointestin
tract
also
support
analog
sarscov
regularli
excret
stool
could
isol
cell
cultur
failur
isol
live
stool
may
due
mild
cours
case
one
case
show
intermitt
diarrhea
china
diarrhea
seen
case
studi
therefor
address
whether
shed
stool
render
noninfecti
though
contact
gut
environ
initi
result
suggest
measur
contain
viral
spread
aim
droplet
rather
fomitebas
transmiss
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
prolong
viral
shed
sputum
relev
hospit
infect
control
also
discharg
manag
situat
character
limit
capac
hospit
bed
infecti
diseas
ward
pressur
earli
discharg
follow
treatment
base
present
find
earli
discharg
ensu
home
isol
could
chosen
patient
beyond
day
symptom
less
viral
rna
copi
per
ml
sputum
criteria
predict
littl
residu
risk
infect
base
cell
cultur
serolog
cours
patient
suggest
time
seroconvers
similar
slightli
earlier
sarscov
infect
seroconvers
case
sar
occur
second
week
symptom
sar
mer
igm
detect
significantli
earlier
igg
immunofluoresc
might
part
due
technic
reason
higher
avid
igg
antibodi
outcompet
igm
viral
epitop
assay
igg
deplet
partial
allevi
effect
ifa
laborintens
method
elisa
test
develop
screen
test
neutral
test
necessari
rule
crossreact
antibodi
direct
endem
human
coronavirus
base
frequent
low
neutral
antibodi
titer
observ
coronaviru
infect
develop
particularli
sensit
plaqu
reduct
neutral
assay
consid
titer
observ
simpler
microneutr
test
format
like
provid
suffici
sensit
routin
applic
popul
studi
align
viral
load
cours
seem
abrupt
viru
elimin
time
seroconvers
rather
seroconvers
earli
week
coincid
slow
steadi
declin
sputum
viral
load
whether
certain
properti
glycosyl
pattern
critic
site
glycoprotein
play
role
attenu
neutral
antibodi
respons
need
clarif
case
vaccin
approach
target
mainli
induct
antibodi
respons
aim
induc
particularli
strong
antibodi
respons
order
effect
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
n
f
l
u
e
n
z
n
r
c
r
n
v
r
u
c
v
n
g
p
r
e
e
p
r
n
h
r
e
e
x
p
r
e
e
u
l
p
l
e
e
n
h
u
n
r
e
p
r
r
n
g
r
n
e
n
l
r
c
p
l
n
e
e
j
u
r
n
l
p
n
e
b
e
l
u
z
r
c
h
u
v
c
w
h
k
e
r
g
r
c
v
n
f
h
e
r
c
r
n
v
r
u
p
k
e
p
r
e
n
v
e
q
u
e
n
l
p
r
e
l
c
c
l
e
v
g
e
w
n
c
e
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
isol
success
base
probit
distribut
inner
line
probit
curv
doserespons
rule
outer
dot
line
ci
less
isol
success
estim
day
ci
day
postonset
estim
rna
concentr
less
isol
success
estim
rnaml
ci
h
subgenom
viral
rna
transcript
relat
viral
genom
rna
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
sputumand
stool
sampl
taken
ship
nativ
condit
oroand
nasopharyng
throat
swab
preserv
ml
viral
transport
medium
viral
load
sputum
sampl
project
rna
copi
per
ml
stool
copi
per
g
throat
swab
copi
per
ml
assum
sampl
compon
suspend
ml
viral
transport
medium
swab
sampl
suspend
less
ml
viral
transport
medium
convers
adapt
repres
copi
per
whole
swab
aggreg
overview
sampl
receiv
per
day
post
onset
diseas
patient
shown
figur
rtpcr
use
target
eand
rdrp
gene
describ
laboratori
use
preformul
oligonucleotid
mixtur
tibmolbiol
berlin
germani
make
laboratori
procedur
reproduc
patient
also
test
respiratori
virus
viru
isol
done
two
laboratori
vero
cell
suspend
clear
filter
clinic
sampl
mix
equal
volum
cell
cultur
medium
supernat
harvest
day
use
rtpcr
analysi
addit
technic
detail
provid
section
supplementari
appendix
perform
recombin
immunofluoresc
assay
determin
specif
reactiv
recombin
spike
protein
cell
describ
assay
use
clone
cov
spike
protein
screen
dilut
plaqu
reduct
neutral
test
done
essenti
previous
describ
merscov
serum
dilut
caus
plaqu
reduct
record
titer
addit
technic
detail
provid
section
supplementari
appendix
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
statist
analys
done
use
spss
softwar
version
grappad
prism
version
patient
provid
inform
consent
use
data
clinic
sampl
purpos
present
studi
institut
review
board
clearanc
scientif
use
patient
data
grant
treat
institut
ethikkommiss
bei
der
medizinischen
der
ludwig
maximillian
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
